Drug Profile
Research programme: transdermal NSAIDs - SK Drug Development Center
Alternative Names: YKPPNLatest Information Update: 10 Jul 2009
Price :
$50
*
At a glance
- Originator SK Bio-Pharmaceuticals
- Developer SK Drug Development Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 01 Jan 2009 Discontinued - Preclinical for Pain in South Korea (unspecified route)
- 17 Aug 2005 Preclinical trials in Pain in South Korea (unspecified route)